Zhiyong Yang, None;
Andrew Tatham, None;
Naama Hammel, None;
Lucie Sharpsten, None;
Felipe Medeiros, Alcon (F), Alcon (R), Allergan (C), Allergan (F), Allergan (R), Bausch & Lomb (F), Carl Zeiss (C), Carl Zeiss (F), Carl Zeiss (R), Heidelberg Engineering (F), Merck (F), National Eye Institute at NIH (F), Novartis (C), Reichert (F), Reichert (R), Senisimed (F), Topcon (F);
Robert Weinreb, Aerie (F), Alcon (C), Allergan (C), Amatek (C), Aquesys (C), Bausch & Lomb (C), Carl Zeiss (C), Carl Zeiss (F), Genentech (F), Heidelberg Engineering (F), Nidek (F), Novartis (F), Optovue (F), Topcon (C), Topcon (F), Valeant (C);
Christopher Girkin, Carl Zeiss (F), EyeSight Foundation of Alabama (F), Heidelberg Engineering (F), National Eye Institute at NIH (F), Research to Prevent Blindness (F), SOLX (F);
Jeffrey Liebmann, Alcon (C), Allergan (C), Allergan (F), Bausch & Lomb (C), Bausch & Lomb (F), Carl Zeiss (F), Diopysis (C), Diopysis (F), Heidelberg Engineering (C), Heidelberg Engineering (F), Merz Pharmaceuticals (C), Optovue (F), Quark Pharmaceuticals (F), Reichert (F), Sensimed (F), Topcon (F), Valeant Pharmaceuticals (C);
Linda Zangwill, Carl Zeiss (F), Carl Zeiss Meditec (P), Heidelberg Engineering (F), Nidek (F), Optovue (F), Quark (F), Topcon (F)